ALX Oncology’s (ALXO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note issued to investors on Tuesday,Benzinga reports.

Several other research analysts also recently commented on ALXO. Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. UBS Group reduced their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Stifel Nicolaus reaffirmed a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ALX Oncology has a consensus rating of “Moderate Buy” and an average price target of $12.50.

ALX Oncology Stock Down 0.7 %

Shares of ALXO opened at $1.33 on Tuesday. The company has a market capitalization of $70.14 million, a P/E ratio of -0.45 and a beta of 1.03. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a one year low of $1.30 and a one year high of $17.83. The business’s 50 day simple moving average is $1.72 and its 200-day simple moving average is $5.71.

Institutional Trading of ALX Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co bought a new stake in shares of ALX Oncology in the 1st quarter valued at $27,000. EntryPoint Capital LLC acquired a new stake in ALX Oncology in the 1st quarter valued at about $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the last quarter. Rhumbline Advisers lifted its position in ALX Oncology by 10.8% during the second quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after acquiring an additional 5,360 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after acquiring an additional 6,080 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.